Coming soon for patients taking XARELTO® (rivaroxaban): Janssen CarePath for XARELTO® and Janssen Select will transition to XARELTO withMe. We are simplifying access to our patient support in one location with a new name and look. Savings card and coverage gap benefits will not change.
What is XARELTO®?
XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has no known dietary restrictions and no requirements for frequent blood tests.
How does XARELTO® work with aspirin?
Both XARELTO® and aspirin help prevent serious blood clots from forming and growing—but they work in different ways:
- XARELTO® slows your body's ability to clot by selectively blocking one of the clotting factors found in your blood—an enzyme called Factor Xa ("10a").
- Aspirin is an antiplatelet blood thinner that works by helping to keep platelets (which are pieces of blood cells) from sticking together and forming blood clots.
XARELTO® for people with PAD
XARELTO®, when taken with low-dose aspirin,* may help reduce the risk of a sudden decrease in blood flow to the legs, major amputation, serious heart problems, or stroke in adults with PAD, including adults who have recently had a procedure to improve blood flow to the legs.
*Low-dose aspirin = 75 mg-100 mg once daily.
Almost95%did not have
a cardiovascular
event†
a cardiovascular
event†
Almost95%did not have a cardiovascular event†
Almost85%did not have a major
blood-clotting event post
vascular intervention.‡
blood-clotting event post
vascular intervention.‡
Almost85%did not have a major blood-clotting event post vascular intervention.‡
In a clinical trial,
almost 95% of people with PAD who had recently had a procedure to improve blood flow to the legs and were taking XARELTO® 2.5 mg twice daily, in combination with low-dose aspirin once daily, did not have a heart attack or stroke, or die from a cardiovascular event.†
Around 3% of people taking XARELTO®, in combination with low-dose aspirin, experienced a major bleeding event versus 1% of people taking only low-dose aspirin. That represents about a 1% increase in bleeding versus people taking only low-dose aspirin.
And, in another clinical trial,
almost 85% of people who took XARELTO®, in combination with low-dose aspirin, did not have a heart attack, stroke, sudden decrease in blood flow in the legs, or amputation after vascular intervention.§
Remember, all blood thinners come with a risk of bleeding. Less than 2% of people taking XARELTO® 2.5 mg twice daily in combination with low-dose aspirin experienced a major bleeding event, such as bleeding into the brain.
†The rate of the first event like a stroke, heart attack, or cardiovascular death was 5.1% for people taking XARELTO® plus aspirin vs 6.9% for aspirin alone. Patients were followed for an average of 23 months.
‡§XARELTO®, in combination with aspirin, reduced the rate of stroke, heart attack, poor blood flow in the legs, and amputation vs aspirin alone (15.5% vs 17.8%). Patients were followed for an average length of 30 months.